A University of Manchester research team has secured nearly £1 million in funding to develop snail-inspired soft robots capable of navigating the gastrointestinal tract and delivering cancer drugs directly to colorectal tumor sites. The concept draws from gastropod locomotion — slow, precise, and substrate-independent — to engineer miniature biocompatible robots that can be remotely guided through the gut via external magnetic fields, releasing their therapeutic payload only at the target site. The clinical problem the project is solving is real and persistent: protein kinase inhibitors, a class of drugs with strong potential against colorectal cancer, are currently limited by poor…
Author: Abhay Panchal
Researchers at the University of Geneva have built something the GI field has long been working toward: a stool-based colorectal cancer screening test powered by machine learning that detected 90% of cancer cases — approaching colonoscopy’s 94% detection rate and outperforming every existing non-invasive method. The key innovation wasn’t the use of gut bacteria per se, but the level of precision applied. Rather than analyzing broad bacterial species, the team mapped microbiota at the subspecies level — an intermediate resolution specific enough to capture disease-relevant differences, yet consistent enough to hold across diverse populations.
For decades, CBT for IBS has been treated as a psychological add-on — something referred when medications fall short. That framing is now being firmly corrected. With ACG guidelines recommending it as an early-line option and insurers increasingly recognizing it as a frontline treatment, CBT is gaining the clinical standing it has long deserved. The mechanism is biological as much as behavioral: CBT recalibrates brain-gut signaling, and research has demonstrated measurable changes in limbic activity, gut microbial composition, and symptom outcomes — including 61% of patients in a landmark RCT reporting meaningful improvement after just four home-based sessions.
A new AGA clinical practice update is pushing endoscopists to think beyond generator dials. While electrosurgical units (ESUs) are a staple of therapeutic GI endoscopy, the update makes clear that outcomes are shaped by the interplay of device settings, operator technique, tissue composition, and procedural environment — not any single factor in isolation. Notably, the evidence shows no meaningful difference in major outcomes between cut-predominant and coagulation-predominant currents for colorectal polypectomy, shifting the focus toward individualized, real-time decision-making rather than protocol-driven defaults. The update also elevates two practical priorities: hot snare remains the preferred approach for large pedunculated polyps due…
A Maricopa County jury sided with a gastroenterologist accused of failing to diagnose a fatal bowel obstruction, declining a $26.6 million damages claim brought by the family of Johnny Ballard, who died in 2019. The case centered on a critical clinical decision: whether a CT scan with contrast dye should have been ordered when Ballard presented with severe abdominal pain, rather than the non-contrast scan that was performed. The defense prevailed by establishing that Ballard’s condition — a volvulus, a rare post-gastric-bypass complication — is exceptionally difficult to detect without the clarity of hindsight. Dr. Chadha’s team argued that the…
Olympus and Canon have launched the Aplio i800 EUS system in the U.S., aiming to improve visualization in complex hepatobiliary and pancreatic conditions—areas where diagnosis remains challenging. The system combines high-resolution imaging with workflow features like automated gain and full-focus imaging, designed to support more consistent and efficient procedures. The signal: As EUS adoption grows, vendors are competing less on access—and more on image quality and procedural efficiency.
United Digestive (UD), one of the largest physician practice management companies supporting gastrointestinal providers and partner practices throughout the Southeast, is driving significant organic growth through strategic investments in new clinics and endoscopy centers, the recruitment of top physician and advanced practice provider talent across its network, and the implementation of new ancillaries to expand its comprehensive care model. Together, these efforts are improving access, reducing wait times, and bringing high-quality GI care closer to patients across UD’s network. “Organic growth has always been a core pillar of our organization’s strategic initiatives” said Neal C. Patel, MD, CEO of United…
GLP-1 receptor agonists are rapidly evolving from diabetes and weight-loss drugs into broader cardiometabolic therapies, with emerging anti-inflammatory and potential neuroprotective benefits. But their expansion comes with a clear clinical constraint: gastrointestinal tolerability. From nausea and delayed gastric emptying to higher discontinuation rates, GI side effects remain the primary barrier to sustained use—shaping both patient adherence and procedural considerations in practice. The shift is clear: GLP-1s are no longer niche therapies—but managing their GI impact is becoming central to their real-world success.
Medical gaslighting, defined as the dismissal or minimization of patient-reported symptoms in the absence of adequate justification, has emerged as a relevant yet insufficiently examined phenomenon in gastroenterology. Patients with gastrointestinal disorders are particularly vulnerable due to the prevalence of conditions that rely on subjective symptom reporting, evolving diagnostic criteria, and limited availability of definitive biomarkers, especially among functional gastrointestinal disorders and disorders of gut-brain interaction as defined by the Rome IV criteria.
A new ranking of America’s most innovative companies highlights a broad shift in how innovation is defined in healthcare—spanning not just new products, but processes and culture. From pharma giants to health systems and AI startups, 53 healthcare organizations made the list, reflecting innovation across the entire care continuum. What stands out is that innovation is no longer limited to breakthrough therapies. It now includes digital transformation, operational efficiency, and the ability to embed innovation into organizational culture. The implication is clear: In healthcare, innovation is becoming less about isolated breakthroughs—and more about system-wide capability.